Business Wire

DEEP-DIVE-GLOBAL-CANAL

24.11.2022 12:23:38 CET | Business Wire | Press release

Share
Deep Dive Global Canal Rowing Action Concludes World Tour With Fruitful Achievements

Covering more than 100 cities in five continents in more than one year, the Deep Dive Global Canal Rowing Action concluded its last leg of the world tour with a global rowing relay in around 20 cities worldwide recently, highlighted the action with fruitful achievements.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221124005072/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Jean-Christophe Rolland, World Rowing Federation president (L3) delivers special honor certificate to Wang Shi (R3), honorary president of Asian Rowing Federation and the action’s team leader in Sharm El-Sheikh during the 2022 United Nations Climate Change Conference (COP27) on 14 Nov. 2022. (Photo: Business Wire)

“On the same day, we held great celebrations both in Yangzhou, a major city along the ancient China’s Grand Canal, and in Cairo, one of the most famous cities along the Nile, the longest river worldwide,” said Feng Nan, president of Deep Dive Sports and Health of China and the organizer of the action. “The two cities thousands of kilometers apart, together with other cities participated and witnessed the successful action, making a clear sign that action has won wide endorsement."

The Deep Dive Action, initially co-organized by the World Historic and Cultural Canal Cities Cooperation Organization (WCCO), an international organization headquartered in Yangzhou, and the Shenzhen Foundation for International Exchange and Cooperation (SFIEC) of China, is aiming to promote the idea of sports, health and environmental protection by holding rowing events in canal cities around the world.

“It’s a milestone in the history of rowing. It’s also a great worldwide environmental awareness campaign,” Feng stressed.

Starting from China’s Grand Canal in September 2021, the campaign has been held successfully on the Potomac River in Washington, the Thames in London, the Seine in Paris, the Donau in Vienna, etc., attracting more than 2,000 international paddlers.

Jean-Christophe Rolland, World Rowing Federation president, highly praised the event. “More important was the powerful message carried out by this mission, which connected and inspired the rowing family to make a difference in this regard,” he stated in a signed letter.

At a side event held in Sharm El-Sheikh during the 2022 United Nations Climate Change Conference (COP27), Rolland also delivered his appreciation especially to Wang Shi, honorary president of Asian Rowing Federation and the action’s team leader, “It is great to see your incredible environmental advocacy, initiated during your presidency at the Asian Rowing Federation, and continuing since.”

“The action connected different cities and different cultures, and raised environmental awareness of many people under the slogan of ‘zero carbon, zero waste and clean water’,” Feng added, “A new plan of the campaign for the next year is in the pipeline.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221124005072/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye